Bio-Techne Corporation
- Open
- 72.36
- Day high
- 72.39
- Day low
- 72.32
- Prev close
- 72.30
- Volume
- 765K
- Mkt cap
- $11.3B
- P/E (TTM)
- 61.9
- EPS (TTM)
- $1.17
- P/B
- 5.4
- P/S
- 9.3
- Yield
- 0.44%
- Per share
- $0.32
Bio-Techne Corporation (TECH) is a Healthcare company listed on NASDAQ. The stock is up 36% over the past year. Drillr has 1 published research article covering TECH.
Bio-Techne Corporation (TECH) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 11 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TECH earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 12, 2026 | $0.52 | $0.52 | +0.2% | $321M | +2.1% |
| May 6, 2026 | $0.55 | $0.53 | -3.6% | $311M | -1.5% |
| Feb 4, 2026 | $0.43 | $0.46 | +7.0% | $296M | -6.5% |
| Nov 5, 2025 | $0.42 | $0.42 | -0.3% | $287M | -1.6% |
| Aug 6, 2025 | $0.50 | $0.53 | +6.0% | $317M | +7.6% |
| May 7, 2025 | $0.51 | $0.56 | +9.8% | $316M | -2.8% |
| Feb 5, 2025 | $0.38 | $0.42 | +10.5% | $297M | -6.5% |
| Oct 30, 2024 | $0.38 | $0.42 | +10.5% | $290M | +3.3% |
| May 1, 2024 | $0.46 | $0.48 | +4.3% | $303M | -0.9% |
| Feb 1, 2024 | $0.42 | $0.40 | -4.8% | $273M | -1.9% |
| Oct 31, 2023 | $0.44 | $0.41 | -6.8% | $277M | -5.0% |
| May 3, 2023 | $0.53 | $0.53 | -0.2% | $294M | -1.2% |
TECH insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Crouse Steven C.officer: President - Diag & Spatial Bi | Grant | 8,702 | — |
| Aug 19, 2026 | Geist Williamofficer: PRESIDENT, PROTEIN SCIENCES | Grant | 23,985 | — |
| Aug 19, 2026 | Bohnen Shaneofficer: SVP - General Counsel | Grant | 18,432 | — |
| Aug 19, 2026 | Geist Williamofficer: PRESIDENT, PROTEIN SCIENCES | Grant | 14,762 | — |
| Aug 19, 2026 | Kelderman Kimdirector, officer: Chief Executive Officer | Grant | 93,582 | — |
| Aug 19, 2026 | Hippel Jamesofficer: CFO | Grant | 22,438 | — |
| Aug 19, 2026 | Hippel Jamesofficer: CFO | Grant | 36,459 | — |
| Aug 19, 2026 | Kelderman Kimdirector, officer: Chief Executive Officer | Grant | 57,590 | — |
| Aug 19, 2026 | Crouse Steven C.officer: President - Diag & Spatial Bi | Grant | 14,140 | — |
| Aug 19, 2026 | Bohnen Shaneofficer: SVP - General Counsel | Grant | 11,344 | — |
| Aug 19, 2026 | Herr Amy E.director | Grant | 1,381 | — |
| Aug 18, 2026 | Kelderman Kimdirector, officer: Chief Executive Officer | Tax | 10,821 | $72.40 |
| Aug 18, 2026 | Hippel Jamesofficer: CFO | Option | 866 | — |
| Aug 18, 2026 | Kelderman Kimdirector, officer: Chief Executive Officer | Option | 8,543 | — |
| Aug 18, 2026 | Bohnen Shaneofficer: SVP - General Counsel | Option | 4,350 | — |
Source: TECH SEC Form 4 filings, latest Aug 19, 2026. For informational purposes only — not investment advice.
See the full TECH insider & 13F page →Bio-Techne Corporation company profile
Overview
Bio-Techne Corporation (NASDAQ:TECH) is a Minneapolis-based biotechnology company founded in 1976 that develops, manufactures, and sells life science research tools and diagnostic products worldwide. Originally known as Techne Corporation until 2014, the company has grown through strategic acquisitions and organic expansion to become a leading provider of biological reagents, instruments, and services serving the research and clinical diagnostic markets. Bio-Techne operates through two primary business segments and has established itself as a critical supplier to pharmaceutical companies, biotechnology firms, academic institutions, and clinical laboratories globally.
Business
Bio-Techne operates in the life sciences tools and diagnostics industry, providing essential products that enable biological research, drug development, and medical diagnostics. The company's offerings span the entire continuum from basic research to clinical applications. The Protein Sciences segment represents the larger portion of the business, generating approximately 72% of total revenue. This division develops and manufactures biological reagents used in life science research, including cytokines and growth factors (signaling proteins that regulate cell behavior), antibodies (proteins that bind to specific targets), small molecules, tissue culture sera, and cell selection technologies. The segment also produces proteomic analytical tools, including automated western blot systems (used to detect specific proteins in samples) and multiplexed ELISA workflow instruments (which can measure multiple proteins simultaneously in biological fluids). The Diagnostics and Spatial Biology segment accounts for approximately 28% of revenue and focuses on clinical diagnostic applications. This division develops diagnostic products including controls and calibrators (reference materials used to ensure test accuracy), diagnostic assays for regulated medical testing, exosome-based molecular diagnostic assays (tests that analyze tiny cellular particles for disease markers), and advanced tissue-based in-situ hybridization assays for spatial genomic analysis (techniques that show where specific genes are active within tissue samples). The segment also produces genetic carrier screening tests, oncology diagnostics, and various instruments for blood chemistry, hematology, and coagulation testing. The company's products are sold under several established brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. These tools are essential for understanding biological processes, developing new medicines, and diagnosing diseases.
Revenue model
Bio-Techne generates revenue primarily through product sales of consumable reagents, instruments, and diagnostic kits to customers across multiple end markets. The company's business model combines recurring consumable sales with higher-margin instrument placements that drive ongoing reagent consumption. The primary customer base includes large pharmaceutical companies, which have shown double-digit growth and represent the most stable revenue source. Biotechnology companies form another significant customer segment, though this market has experienced volatility due to funding challenges. Academic institutions represent approximately 11% of total revenue, with less than 1% directly tied to NIH funding. Clinical laboratories and diagnostic companies purchase the company's diagnostic products and spatial biology platforms. Revenue streams include consumable reagents that require regular replenishment, instruments with typical selling prices ranging from tens of thousands to several hundred thousand dollars (such as the Comet spatial biology platform at approximately $350,000), and diagnostic test kits with per-test pricing models. The cell and gene therapy business has shown particularly strong growth, with GMP (Good Manufacturing Practice) reagents growing over 90% in recent quarters. Several factors influence the company's margins and growth trajectory. Positive factors include the increasing adoption of cell and gene therapies driving demand for specialized reagents, the growing trend toward personalized medicine requiring advanced diagnostic tools, expansion in emerging markets, and the company's ability to command premium pricing for innovative products. Challenging factors include biotech funding volatility affecting customer spending, academic budget constraints, competitive pressure in commodity reagent markets, regulatory changes affecting diagnostic product approvals, and macroeconomic factors influencing research and development spending across the industry.
Competitive moat
Bio-Techne possesses a moderate to strong competitive moat built on several key advantages. The company benefits from significant switching costs, as researchers and clinicians invest considerable time validating specific reagents and protocols, making them reluctant to change suppliers once established workflows are in place. This creates customer stickiness particularly strong in the consumables business. The company's extensive product portfolio spanning over 750,000 products provides cross-selling opportunities and makes Bio-Techne a one-stop shop for many customers, increasing wallet share and reducing the likelihood of customer defection. The breadth also creates barriers for smaller competitors who cannot match this comprehensive offering. Technical expertise and regulatory knowledge represent another moat component, particularly in the diagnostics segment where products must meet stringent FDA and international regulatory requirements. The company's experience navigating these complex approval processes creates barriers for new entrants. However, the moat faces several challenges. The life sciences tools market is highly competitive with large players like Thermo Fisher Scientific, which has significantly greater scale and resources. Many of Bio-Techne's products, particularly basic reagents, face commoditization pressure as patents expire and biosimilar alternatives emerge. The company's smaller size relative to industry giants limits its bargaining power with large pharmaceutical customers and its ability to invest in R&D at the same scale as competitors. The rapid pace of technological change in areas like spatial biology and molecular diagnostics also poses risks, as breakthrough technologies from startups or tech giants could potentially disrupt established product categories. While Bio-Techne has invested in innovation and strategic acquisitions to stay competitive, maintaining technological leadership requires continuous significant investment.
Risks & safety
Bio-Techne demonstrates a strong financial position with solid liquidity and manageable debt levels, though current valuation metrics suggest limited margin of safety. • Liquidity and Solvency: Strong current ratio of 3.7x, quick ratio of 2.6x, and $140.7 million in cash provides substantial financial cushion. Debt-to-equity ratio of 0.21x indicates conservative capital structure with low solvency risk. • Cash Generation: Positive free cash flow of $31.0 million in Q3 2025, though down from stronger historical levels. Operating cash flow of $41.1 million demonstrates underlying business cash generation capability. • Valuation Concerns: EV/EBITDA of 61.4x appears extremely elevated, suggesting significant valuation risk. Price-to-book ratio of 4.6x indicates premium valuation relative to tangible assets. • Profitability Metrics: Return on equity of 1.1% is concerningly low, indicating poor capital efficiency. Net margin of approximately 7% is modest for a life sciences tools company. • Other Considerations: Graham number analysis suggests potential overvaluation, though the company's asset-light business model may justify some premium. Dividend payments and share buybacks totaling $112.6 million in recent quarters demonstrate management's confidence and commitment to shareholder returns.
Recent development
Over the past few years, Bio-Techne has executed several strategic initiatives to position itself for long-term growth in high-value market segments. The company has focused on building four key growth verticals that now represent 45% of total revenue, up from 30% five years ago: cell and gene therapy workflow solutions, protein analysis platforms, spatial biology technologies, and molecular diagnostics. In cell and gene therapy, the company has significantly expanded its GMP reagent manufacturing capabilities and now serves over 500 customers, with 85 customers in clinical trials. This business has shown remarkable growth with GMP reagents increasing over 90% in recent quarters and the overall cell therapy portfolio growing over 30% on a trailing twelve-month basis. The spatial biology platform has been strengthened through the acquisition of Lunaphore and the launch of the Comet system, which offers unique multi-omic capabilities allowing simultaneous visualization of 24 proteins and 12 RNA targets. Manufacturing capacity constraints for this high-demand platform have been addressed to meet growing customer demand. In protein analysis, Bio-Techne launched the next-generation LEO high-throughput platform and has seen instrument placements grow for the first time in two years, with consumable growth in 8 out of 9 recent quarters. The company has also embraced artificial intelligence initiatives, adding designer proteins with enhanced functionality and leveraging AI for protein engineering. Additionally, Bio-Techne has diversified its geographic manufacturing footprint to mitigate potential tariff impacts and established strategic partnerships, including one with Thermo Fisher Scientific, to enhance its commercial reach.
TECH company profile · for informational purposes only — not investment advice.
Track TECH with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free